SOPH (Sophia Genetics) ROCE %: -62.46% (As of Mar. 2026)


SOPH Sophia Genetics SA SOPH
72 GF Score
Price $5.87
GF Value $5.03
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sophia Genetics ROCE %?

Sophia Genetics SOPH +2.99% 72 ROCE % is -62.46% as of Mar. 2026. GuruFocus rates SOPH with a GF Score™ of 72/100 and a GF Value™ of $5.03 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sophia Genetics's annualized ROCE % for the quarter that ended in Mar. 2026 was -62.46%.

Sophia Genetics  (NAS:SOPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sophia Genetics ROCE % Related Terms

Sophia Genetics ROCE % Historical Data

* Premium members only.

The historical data trend for Sophia Genetics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sophia Genetics ROCE % Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -36.23 -34.19 -40.20 -39.70 -60.52

Sophia Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.70 -64.68 -52.56 -59.91 -62.46
SOPH
72GF Score
Sophia Genetics SA SOPH
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sophia Genetics ROCE % Calculation

Sophia Genetics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-72.933/( ( (155.309 - 26.803) + (163.031 - 50.528) )/ 2 )
=-72.933/( (128.506+112.503)/ 2 )
=-72.933/120.5045
=-60.52 %

Sophia Genetics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-69.608/( ( (163.031 - 50.528) + (156.995 - 46.595) )/ 2 )
=-69.608/( ( 112.503 + 110.4 )/ 2 )
=-69.608/111.4515
=-62.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -62.46% mean?
Sophia Genetics (SOPH) has a ROCE % of -62.46% as of Mar. 2026.
Is Sophia Genetics' ROCE % too high?
Sophia Genetics' current ROCE % is -62.46%. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' ROCE % compare to SLP and TBRG?
Sophia Genetics' ROCE % of -62.46% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current ROCE % is -62.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.03, compared to a current price of $5.87 — trading 16.6% above its estimated fair value. The current ROCE % is -62.46%. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current ROCE % is -62.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sophia Genetics (SOPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued. The current stock price of $5.87 is trading 16.6% above its estimated GF Value™ of $5.03. GuruFocus considers Sophia Genetics to be Modestly Overvalued.

Key valuation signals for SOPH:

  • ROCE %: -62.46%
  • GF Value™: $5.03 vs. price of $5.87 (16.6% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sophia Genetics Business Description

Other Exchanges 90B:Germany
Address La Piece 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score

Get the complete analysis for SOPH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.87
Price
$5.03
GF Value